Financial Performance - The company's operating revenue for 2024 was ¥853,024,340.06, a decrease of 27.76% compared to ¥1,180,897,087.04 in 2023[23]. - The net profit attributable to shareholders for 2024 was -¥925,169,864.75, representing a decline of 983.98% from a profit of ¥104,659,624.06 in 2023[24]. - The net cash flow from operating activities decreased by 61.50% to ¥300,332,716.60 in 2024, down from ¥780,111,104.70 in 2023[24]. - The total assets at the end of 2024 were ¥9,576,915,691.47, a reduction of 13.08% from ¥11,017,916,882.14 at the end of 2023[24]. - The net assets attributable to shareholders decreased by 11.26% to ¥7,879,949,193.44 at the end of 2024, down from ¥8,880,234,790.09 at the end of 2023[24]. - The basic and diluted earnings per share for 2024 were both -¥0.66, a significant drop from ¥0.07 in 2023, marking a decline of 1,042.86%[24]. - The weighted average return on equity for 2024 was -11.04%, down from 1.08% in 2023, indicating a decrease of 12.12%[24]. - The company reported a total profit for the period of -¥1,071,163,394.40, representing a decrease of 1043.46% year-over-year[66]. Cash Flow and Investments - The net cash flow from operating activities for 2024 was CNY 300.33 million, a decrease of 61.50% compared to CNY 780.11 million in 2023, primarily due to a reduction in accounts receivable collections[112]. - The net cash flow from investing activities was -CNY 217.39 million in 2024, a significant decrease of 241.33% from -CNY 63.69 million in 2023, mainly due to a reduction in maturing financial products[112]. - The net cash flow from financing activities improved to -CNY 205.96 million in 2024, an increase of 91.14% compared to -CNY 2.32 billion in 2023, attributed to a decrease in cash dividend distribution[112]. - The total cash inflow from operating activities was CNY 2.42 billion in 2024, down 44.48% from CNY 4.35 billion in 2023[111]. - The total cash outflow from operating activities was CNY 2.12 billion in 2024, a decrease of 40.76% from CNY 3.57 billion in 2023[111]. Market and Industry Outlook - The biopharmaceutical industry is expected to continue its growth trajectory, driven by increased health awareness and government support for healthcare initiatives[36]. - The global IVD market has become a $100 billion market, with expected rapid growth driven by new technologies and products[37]. - The domestic IVD market is projected to maintain steady growth, with increasing diagnostic procedures and expanding application fields, particularly in immunodiagnostics and molecular diagnostics[37]. - The domestic IVD industry is experiencing rapid development, with a rise in innovation speed across various technology platforms and an increasing number of application products[37]. - The company aims to become a top-tier, internationally recognized integrated supplier in the IVD industry, focusing on clinical diagnostic technology and product development[43]. Product Development and Innovation - The company has received multiple approvals for various nucleic acid testing kits, including those for COVID-19 and influenza viruses, indicating a strong product portfolio in the diagnostics sector[45]. - The company is actively expanding its product offerings with new test kits for pathogens like human immunodeficiency virus (HIV) and human papillomavirus (HPV)[45]. - The introduction of genetic testing kits for conditions like thalassemia and hereditary deafness indicates the company's commitment to genetic diagnostics[45]. - The company is focusing on expanding its product offerings in the immunoassay and mass spectrometry testing segments, which are expected to drive future revenue growth[53]. - The company is investing in research and development for new technologies, aiming to innovate in the field of medical diagnostics[53]. Strategic Initiatives and Partnerships - The company is exploring strategic partnerships to enhance its distribution network and market reach, particularly in underserved regions[46]. - The company has established a national multi-level business platform and a three-tier operational support system to enhance market penetration and service quality[67]. - The company is committed to expanding its market presence both domestically and internationally, with a focus on the IVD field and various diagnostic technology applications[136]. - The company is actively pursuing potential acquisitions to bolster its technological capabilities and expand its product offerings in the diagnostics market[46]. Governance and Compliance - The company has implemented a transparent performance evaluation and incentive mechanism for directors and senior management[160]. - The company ensures timely and accurate information disclosure, providing equal access to information for all shareholders[161]. - The company respects the rights of stakeholders and promotes balanced interests among shareholders, employees, and society[162]. - The company has developed independent operational capabilities and a complete supply, production, and sales system separate from its controlling shareholder[164]. - The company has established a value management system and disclosed a valuation enhancement plan[151][152].

证券代码：002030 证券简称：达安基因 公告编号：2025-004 广州达安基因股份有限公司 关于下属子公司取得一个医疗器械注册证的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 董 事 会 2025 年 2 月 13 日 近日，本公司下属控股子公司广州市达瑞生物技术股份有限公司取得国家药 品监督管理局颁发的医疗器械注册证一个，具体为： 医疗器械名称:梅毒螺旋体抗体检测试剂盒（化学发光免疫分析法），注册证 编号：国械注准 20253400374。有效期自批准之日起至 2030 年 2 月 10 日。预期 用途：本试剂盒用于体外定性检测人血清或血浆中的梅毒螺旋体抗体。 目前，公司控股子公司广州市达瑞生物技术股份有限公司已获得"梅毒螺旋 体抗体检测试剂盒（化学发光免疫分析法）"的医疗器械注册证，上述产品尚处 于市场开发阶段，市场需求存在不确定性，敬请投资者注意风险。 特此公告。 广州达安基因股份有限公司 ...

证券代码：002030 证券简称：达安基因 公告编号：2025-003 广州达安基因股份有限公司 第八届董事会 2025 年第一次临时会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 公司经营班子根据企业战略发展目标和业务规划要求，尽快制订新激励制度， 并报董事会审定。 2020 年至 2022 年期间累积留存至高管人员现金激励奖金池的奖金依据新的 考核和激励制度执行。 二、会议以 6 票赞成，0 票反对，0 票弃权的表决结果审议通过了公司《关 于发放 2024 年高级管理人员两个月职级工资的议案》。关联董事黄珞女士、张斌 先生、蒋析文先生回避表决。 根据公司《薪酬管理制度》和《绩效管理制度》，结合 2024 年度全体高级管 理人员的工作表现，高级管理人员 2024 年度增加发放两个月职级工资。 特此公告。 广州达安基因股份有限公司 广州达安基因股份有限公司(以下简称"公司"、"达安基因")于 2025 年 1 月 22 日以邮件的形式发出会议通知，并于 2025 年 1 月 27 日（星期一）上午 10∶ 00 在广州市高新区科学城香山路 19 ...

Financial Performance Expectations - The company expects a net profit loss for the year 2024, estimated between -74 million to -99 million CNY, compared to a profit of 10.47 million CNY in the same period last year[3] - The net profit after deducting non-recurring gains and losses is projected to be between -70 million to -94 million CNY, compared to a loss of 36.38 million CNY in the previous year[3] - Basic earnings per share are expected to be between -0.53 to -0.71 CNY, down from a profit of 0.07 CNY per share in the same period last year[3] Reasons for Decline in Profit - The decline in net profit is primarily due to reduced market demand and price adjustments, leading to decreased operating revenue[5] - Losses from affiliated enterprises have contributed to the decline in net profit attributable to shareholders[5] - Increased provisions for bad debts on accounts receivable have negatively impacted net profit[6] - The fair value of other non-current financial assets has decreased, further affecting net profit, classified as non-recurring losses[6] Financial Reporting and Investor Guidance - The financial data presented is preliminary and has not been audited by an external accounting firm[4] - The company will disclose detailed financial data in the 2024 annual report[7] - Investors are advised to make cautious decisions and be aware of investment risks[7]

医疗器械名称：遗传性耳聋基因检测试剂盒（PCR-流式荧光杂交法），注册 证编号：国械注准 20243402614。有效期自批准之日起至 2029 年 12 月 16 日。 预期用途：本试剂盒用于体外定性检测新生儿干血斑样本基因组 DNA 中 4 个遗传 性耳聋基因中的 17 个位点，包括 GJB2（35 delG、176_191 del16、235 delC、 299_300 delAT、511_512 insAACG 位点）、GJB3（538 C>T 位点）、SLC26A4（1174 A>T、1226 G>A、1229 C>T、1975 G>C、2027 T>A、2162C>T、2168 A>G、IVS7-2 A>G、IVS15+5 G>A 位点）和线粒体 12SrRNA 基因（1494 C>T、1555 A>G 位点） 突变。 上述医疗器械注册证的取得丰富了公司的产品组合，拓宽了公司产品的应用 领域。目前，上述产品尚处于市场开发阶段，市场需求存在不确定性，请广大投 资者注意投资风险。 特此公告。 证券代码：002030 证券简称：达安基因 公告编号：2024-059 广州达安基因股份有限公司 关于取得一个 ...

医疗器械名称：呼吸道合胞病毒 A 型和 B 型核酸检测试剂盒（PCR-荧光探针 法），注册证编号：国械注准 20243402489。有效期自批准之日起至 2029 年 12 月 12 日。预期用途：用于体外定性分型检测人口咽拭子样本中呼吸道合胞病毒 A 型和 B 型核酸。 上述医疗器械注册证的取得丰富了公司的产品组合，拓宽了公司产品的应用 领域。目前，上述产品尚处于市场开发阶段，市场需求存在不确定性，请广大投 资者注意投资风险。 证券代码：002030 证券简称：达安基因 公告编号：2024-058 广州达安基因股份有限公司 关于取得一个医疗器械注册证的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，广州达安基因股份有限公司（以下简称"公司"）取得国家药品监督 管理局颁发的医疗器械注册证一个，具体为： 特此公告。 广州达安基因股份有限公司 董 事 会 2024 年 12 月 16 日 ...

证券时报e公司讯，①达安基因：近日公司取得国家药品监督管理局颁发的医疗器械注册证两个，具体 为：1、医疗器械名称：甲型流感病毒、乙型流感病毒和呼吸道合胞病毒核酸检测试剂盒（PCR-荧光探 针法），预期用途：产品用于对人咽拭子样本中的甲型流感病毒、乙型流感病毒和呼吸道合胞病毒 RNA进行定性检测；2、医疗器械名称：甲型/乙型流感病毒核酸检测试剂盒（PCR-荧光探针法），预 期用途：产品用于体外定性检测人咽拭子样本中甲型流感病毒和乙型流感病毒RNA。 ②艾德生物：公司于近日获得由国家药品监督管理局颁发的《中华人民共和国医疗器械注册证》，产品 名称：孕激素受体抗体试剂（免疫组织化学法），预期用途：试剂盒用于体外半定量检测经10%中性缓 冲福尔马林固定石蜡包埋（FFPE）组织切片中孕激素受体。 ...

证券代码：002030 证券简称：达安基因 公告编号：2024-057 广州达安基因股份有限公司 董 事 会 近日，广州达安基因股份有限公司（以下简称"公司"）取得国家药品监督 管理局颁发的医疗器械注册证两个，具体为： 1、医疗器械名称：甲型流感病毒、乙型流感病毒和呼吸道合胞病毒核酸检 测试剂盒（PCR-荧光探针法），注册证编号：国械注准 20243402390。有效期自 批准之日起至 2029 年 11 月 26 日。预期用途：本产品用于对人咽拭子样本中的 甲型流感病毒、乙型流感病毒和呼吸道合胞病毒 RNA 进行定性检测。 2、医疗器械名称：甲型/乙型流感病毒核酸检测试剂盒（PCR-荧光探针法）， 注册证编号：国械注准 20243402392。有效期自批准之日起至 2029 年 11 月 26 日。预期用途：本产品用于体外定性检测人咽拭子样本中甲型流感病毒和乙型流 感病毒 RNA。 上述医疗器械注册证的取得丰富了公司的产品组合，拓宽了公司产品的应用 领域。目前，上述产品尚处于市场开发阶段，市场需求存在不确定性，请广大投 资者注意投资风险。 特此公告。 广州达安基因股份有限公司 关于取得两个医疗器械注册证的提 ...

附件: 热烈欢迎机构投资者 莅临达安基因调研 l 窒蜜佩解决方案 n 2008 2006 - 注：左六为公司董事会秘书张斌与调研人员合影留念。 ...

证券代码：002030 证券简称：达安基因 广州达安基因股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | |-----------------------|--------------------------------------------------------|-----------------|----------------|---------| | | | | 编号： | 2024006 | | | √ 特定对象调研 | □ 分析师会议 | | | | | □ 媒体采访 | □ 业绩说明会 | | | | 投资者关系活动 | □ 新闻发布会 | □ 路演活动 | | | | 类别 | √ 现场参观 | | | | | | □ 其他（） | | | | | | 宁波知远投资 | 杨桑 | | | | | 浙江思悦投资 | 刘骏池 | | | | | 广州图灵投资 | 周书冬 | | | | 参与单位名称及 | 深圳泽源投资 | 吴文贵 张柘豪 | | | | 人员姓名 | 深圳蓝马资本 | 韩圣洁 | | | | | 广州顺从私募证券投资基金 | 邱 ...